Section Arrow
ALXO.NASDAQ
- ALX Oncology Holdings
(Financial Status)
Quotes are at least 15-min delayed:2025/07/10 08:09 EDT
Last
 0.5003
+0.0416 (+9.07%)
Day High 
0.5098 
Prev. Close
0.4587 
1-M High
0.63 
Volume 
834.08K 
Bid
0.5005
Ask
0.508
Day Low
0.4526 
Open
0.4526 
1-M Low
0.404 
Market Cap 
24.51M 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 0.44 
20-SMA 0.48 
50-SMA 0.49 
52-W High 8.78 
52-W Low 0.404 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-2.45/-0.72
Enterprise Value
33.98M
Balance Sheet
Book Value Per Share
1.65
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
NCNANuCana plc0.0603+0.0047+8.45%-- 
CLDICalidi Biotherapeutics0.7+0.365+108.96%-- 
PROKProKidney Corp4.34+0.61+16.35%-- 
ASBPAspire Biopharma Holdings Inc.0.326+0.0129+4.12%-- 
VRNAVerona Pharma plc104.77+17.91+20.62%-- 
Quotes are at least 15-min delayed:2025/07/10 08:09 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.